Phenominer Database Results (30 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
ACI/SegHsd prostate tumorous lesion number control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 5.3 null ex vivo light microscopy 0 65822 341
ACI/SegHsd prostate gland wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate mass male 900.0 days 12 1.54 g post excision weight measurement 0 65828 341
ACI/SegHsd area of ventral prostate occupied by tumorous lesions to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.61 % ex vivo light microscopy with digital image analysis 0.0 67946 341
ACI/SegHsd area of ventral prostate occupied by tumorous lesions with solid structure to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.09 % 0.38 1.31 ex vivo light microscopy with digital image analysis 0.0 109891 341
ACI/SegHsd percentage of study population developing mammary tumors during a period of time control condition Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 201.0 days-518.0 days 3 0.0 % manual palpation method mammary gland 0 11378 76
ACI/SegHsd body weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. body mass male 900.0 days 12 null 419.6 g body weighing method method not specified, assumed to be digital scale 13301 341
ACI/SegHsd thymus wet weight control condition Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. thymus mass male 147.0 days 9 150.0 mg 15.33 46.0 post excision weight measurement 0.0 69097 1121
ACI/SegHsd percentage of study population developing subcutaneous tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. hypodermis integrity trait male 900.0 days 12 0.0 % necropsy 0.0 CMO:0003387 percentage of study population developing subcutaneous tumors during a period of time 106887 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 92.0 % ex vivo light microscopy 0.0 109885 341
ACI/SegHsd number of ventral prostate tumorous lesions with solid structure control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 3.0 null 0.75 2.6 ex vivo light microscopy 0.0 109887 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 100.0 % ex vivo light microscopy 0.0 109957 341
ACI/SegHsd percentage of study population developing ventral prostate tumorous lesions during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 100.0 % ex vivo light microscopy 0 65825 341
ACI/SegHsd ventral prostate gland wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. ventral prostate mass male 900.0 days 12 0.32 g post excision weight measurement 0.0 65826 341
ACI/SegHsd percentage of study population developing leukemia during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. leukocyte integrity trait male 900.0 days 12 0.0 % ex vivo light microscopy 0 leukemia incidence 66143 341
ACI/SegHsd percentage of study population developing bilateral testis tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis integrity trait male 900.0 days 12 25.0 % ex vivo light microscopy 0.0 necropsy bilateral testis tumor incidence 67948 341
ACI/SegHsd absolute change in thymus weight control condition Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. thymus mass male 147.0 days 9 268.0 mg post excision weight measurement 0.0 69098 1121
ACI/SegHsd area of ventral prostate occupied by tumorous lesions with round, irregular size nuclei to total ventral prostate area ratio control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.57 % 0.38 1.31 ex vivo light microscopy with digital image analysis 0.0 109963 341
ACI/SegHsd both testes wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis mass male 900.0 days 12 2.81 g post excision weight measurement 0 65820 341
ACI/SegHsd area of individual prostate tumorous lesion control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.78 mm2 ex vivo light microscopy with digital image analysis 0 65838 341
ACI/SegHsd thymus wet weight control condition Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64. thymus mass male 63.0 days 9 419.0 mg 13.33 40.0 post excision weight measurement 0.0 69096 1121
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. kidney integrity trait male 900.0 days 12 24.0 % necropsy 0.0 106885 341
ACI/SegHsd area of individual ventral prostate tumorous lesion with a solid structure control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.17 mm2 0.36 1.25 ex vivo light microscopy with digital image analysis 0.0 109889 341
ACI/SegHsd number of ventral prostate tumorous lesions with round, irregular size nuclei control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 5.1 null 0.69 2.4 ex vivo light microscopy 0.0 109959 341
ACI/SegHsd area of individual ventral prostate tumorous lesion with round, irregular size nuclei control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. prostate integrity trait male 900.0 days 12 1.73 mm2 0.36 1.24 ex vivo light microscopy with digital image analysis 0.0 109961 341
ACI/SegHsd percentage of study population developing testis tumors during a period of time control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. testis integrity trait male 900.0 days 12 92.0 % ex vivo light microscopy 0.0 testis tumor incidence 65840 341
ACI/SegHsd mammary tumor number control condition Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259.0 days 4 0.0 null necropsy 11367 75
ACI/SegHsd liver wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. liver mass male 900.0 days 12 null 11.3 g post excision weight measurement method not specified, assumed to be digital scale 13303 341
ACI/SegHsd spleen wet weight control condition Yamashita S, et al., Cancer Res 2005 Apr 1;65(7):2610-6. spleen mass male 900.0 days 12 null 0.8 g post excision weight measurement method not specified, assumed to be digital scale 13305 341
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait female  days 96 13.5 % necropsy 0.0 69372 1157
ACI/SegHsd percentage of study population developing unilateral renal agenesis during a period of time control condition Shull JD, et al., Mamm Genome. 2006 Jul;17(7):751-9. Epub 2006 Jul 14. kidney integrity trait male  days 87 5.7 % necropsy 0.0 69374 1157